Company: AEMD
Filing Date: 2025-08-29
Form Type: S-1/A
Source: 0001683168-25-006537
Chunk: 53

Company: AETHLON MEDICAL INC
Filing Date: 2025-08-29
Form: S-1/A
Chunk 53
---
ering would be $0.39 per share, assuming that the number of shares of our common stock and accompanying warrants sold by
us remains the same, after deducting the placement agent fees and estimated offering expenses payable by us.

We may also increase or decrease
the number of shares of common stock and accompanying warrants we are offering from the number of shares of common stock and accompanying
warrants set forth above. An increase of 1.0 million in the assumed number of shares of common stock and accompanying warrants sold
by us in this offering would result in an increase in our as adjusted net tangible book value of approximately $2.1 million, or approximately
$0.29 per share, and the dilution per share to investors purchasing common stock and accompanying warrants in this offering would
be approximately $0.14 per share, assuming that the assumed combined public offering price per share of common stock and accompanying
warrant remains the same, after deducting the placement agent fees and estimated offering expenses payable by us. A decrease of 1.0 million
in the assumed number of shares of common stock and accompanying warrants sold by us in this offering would result in a decrease in our
as adjusted net tangible book value after this offering of approximately $2.1 million, or approximately per share, and the dilution
per share to investors purchasing common stock and accompanying warrants in this offering would be approximately $0.72 per share,
assuming that the assumed combined public offering price per share of common stock and accompanying warrant remains the same, after deducting
the placement agent fees and estimated offering expenses payable by us. The information discussed above is illustrative only and will
adjust based on the actual public offering price, the actual number of shares of common stock and accompanying warrants sold in this
offering and other terms of this offering determined at pricing.

| 30 |

The discussion and table above
assume (i) no exercise of the placement agent’s warrant or the warrants issued in this offering and (ii) no sale of pre-funded
warrants in this offering.

We may choose to raise additional
capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating
plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these
securities could result in further dilution to our stockholders.

The table and discussion
above are based on 2,598,711 shares of our common stock outstanding as of August